Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Antonio Luna-Moran"'
Autor:
William A. Weiss, Neil E. Torbett, Zachary A. Knight, Mark M. Moasser, Antonio Luna-Moran, Kevan M. Shokat, David Stokoe, Andrew R. Houk
Publikováno v:
Biochemical Journal. 415:97-110
The PI3K (phosphoinositide 3-kinase) pathway regulates cell proliferation, survival and migration and is consequently of great interest for targeted cancer therapy. Using a panel of small-molecule PI3K isoform-selective inhibitors in a diverse set of
Autor:
Aaron N. Nguyen, Kyle J. MacBeth, Carla Heise, Normand Richard, Paul W. Hollenbach, Antonio Luna-Moran, Helen Brady
Publikováno v:
Lung Cancer: Targets and Therapy.
Aaron N Nguyen1, Paul W Hollenbach1, Normand Richard2, Antonio Luna-Moran1, Helen Brady2, Carla Heise1, Kyle J MacBeth11Celgene Corporation, San Francisco, CA, USA; 2Celgene Corporation, San Diego, CA, USAAbstract: Azacitidine (AZA) and decitabine (D
Publikováno v:
Cancer Research. 72:1050-1050
Background: Azacitidine (AZA) is approved for treatment of patients with myelodysplastic syndromes or WHO-defined acute myeloid leukemia with multi-lineage dysplasia ( Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 10
Autor:
Normand Richard, Aaron N. Nguyen, Kyle J. MacBeth, Helen Brady, Antonio Luna-Moran, Igor Belka
Publikováno v:
Cancer Research. 70:191-191
Acute myeloid leukemia (AML) is characterized by blast cells that are unable to mature into functional, terminally-differentiated hematopoietic cells. Inducing leukemic cells to differentiate restores a natural cell death program and inhibits prolife
Autor:
Neil E. Torbett, Antonio Luna-moran, Zachary A. Knight, Andrew Houk, Mark Moasser, William Weiss, Kevan M. Shokat, David Stokoe
Publikováno v:
Biochemical Journal; 2008, Vol. 415 Issue 1, p97-110, 14p